P53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent

Details for Australian Patent Application No. 2005215910 (hide)

Owner Novartis Forschungsstiftung Novartis AG

Inventors Thomas, George; Lane, Heidi; O'Reilly, Terence; Boulay, Anne; Beuvink, Iwan

Agent Davies Collison Cave

Pub. Number AU-B-2005215910

PCT Pub. Number WO2005/080593

Priority 60/546,856 23.02.04 US

Filing date 22 February 2005

Wipo publication date 1 September 2005

Acceptance publication date 1 May 2008

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

31 August 2006 PCT application entered the National Phase

  PCT publication WO2005/080593 Priority application(s): WO2005/080593

1 May 2008 Application Accepted

  Published as AU-B-2005215910

28 August 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005215913-Dual or multi-chamber tube

2005215906-Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols